Therapeutic oligonucleotides

The road not taken

Cy A. Stein, Sanjay Goel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

Original languageEnglish (US)
Pages (from-to)6369-6372
Number of pages4
JournalClinical Cancer Research
Volume17
Issue number20
DOIs
StatePublished - Oct 15 2011

Fingerprint

Oligonucleotides
Antisense Oligonucleotides
United States Food and Drug Administration
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapeutic oligonucleotides : The road not taken. / Stein, Cy A.; Goel, Sanjay.

In: Clinical Cancer Research, Vol. 17, No. 20, 15.10.2011, p. 6369-6372.

Research output: Contribution to journalArticle

Stein, Cy A. ; Goel, Sanjay. / Therapeutic oligonucleotides : The road not taken. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 20. pp. 6369-6372.
@article{7b8746d7ee79479fb39dfa6930ffd37b,
title = "Therapeutic oligonucleotides: The road not taken",
abstract = "Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.",
author = "Stein, {Cy A.} and Sanjay Goel",
year = "2011",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-11-2013",
language = "English (US)",
volume = "17",
pages = "6369--6372",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Therapeutic oligonucleotides

T2 - The road not taken

AU - Stein, Cy A.

AU - Goel, Sanjay

PY - 2011/10/15

Y1 - 2011/10/15

N2 - Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

AB - Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

UR - http://www.scopus.com/inward/record.url?scp=80054094688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054094688&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2013

DO - 10.1158/1078-0432.CCR-11-2013

M3 - Article

VL - 17

SP - 6369

EP - 6372

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -